腔内注射泡沫硬化剂与超声引导泡沫硬化剂在静脉腔内消融中的随机对照试验
该随机对照试验比较了EVLA联合经鞘腔内注射泡沫硬化剂(TLFS)与联合超声引导泡沫硬化剂(UGFS)的安全性和疗效。结果显示TLFS组1年VCSS改善更显著,且需二次硬化治疗的比例更低(10% vs 54%)。
要点
- TLFS联合EVLA较UGFS联合EVLA显著改善1年VCSS(-8.7 vs -7.4)。
- TLFS组需二次硬化治疗的比例显著低于UGFS组(10% vs 54%)。
- 两组均实现主干静脉闭合,TLFS是VCSS改善的唯一显著因素。
核心结论
- TLFS联合EVLA安全可行,较UGFS联合EVLA改善VCSS并减少二次干预需求。
研究设计与样本
- 随机对照试验,筛查467例患者(577条腿),随机分配至TLFS组(103条腿)或UGFS组(94条腿)。
主要发现
- 12个月随访时两组主干静脉均闭合,TLFS组VCSS改善显著优于UGFS组(UGFS -7.4±1.8 vs TLFS -8.7±1.5,P<.0001)。
- TLFS组需二次硬化治疗的比例显著低于UGFS组(10% vs 54%,P<.0001)。
- 多因素分析显示TLFS是VCSS改善的唯一显著因素(HR 0.63,95%CI 0.32-0.96,P<.0001)。
关键数值与推荐
- 纳入症状性原发性大隐静脉反流患者,排除既往干预后复发、硬化剂过敏、急性深静脉血栓、严重下肢缺血、凝血障碍及同期双侧主干消融者。
临床怎么用
- 在EVLA治疗大隐静脉反流时,可优先考虑经鞘腔内注射泡沫硬化剂以增强疗效并减少二次干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compared the safety, need for additional foam sclerotherapy, and 1-year venous clinical severity score (VCSS) improvement in the limbs of patients with chronic venous disease and great saphenous vein (GSV) reflux. These patients had undergone endovenous laser ablation (EVLA) using a 1470-nm diode laser and concurrent foam sclerotherapy (1% polidocanol) through the access sheath (transluminal injection of foam sclerotherapy [TLFS]) or EVLA and concurrent direct-puncture ultrasound-guided foam sclerotherapy (UGFS). METHODS: In the present study, we screened 467 patients (577 legs) with symptomatic primary GSV reflux for randomization to either TLFS with EVLA (n = 103 legs; TLFS group) or UGFS with EVLA (n = 94 legs; UGFS group). The exclusion criteria were (1) recurrent varicose veins after previous intervention; (2) hypersensitivity reaction to sclerotherapy; (3) acute deep vein thrombosis; (4) serious lower limb ischemic disease; (5) a coagulation disorder; and (6) simultaneous EVLA of both GSVs and small saphenous veins. The correlations of the VCSS changes with the clinical features, such as age, sex, CEAP (clinical, etiologic, anatomic, pathophysiologic) classification, total amount of sclerosant used at the original procedure, multiple punctures (more than two) for sclerotherapy at the original procedure, the use of TLFS, and linear endovenous energy density, were estimated using logistic regression. RESULTS: No significant differences in the distribution of the CEAP classification were observed between the two groups. After 12 months of follow-up, all truncal veins were occluded. The VCSS had significantly improved in the TLFS group compared with the UGFS group (UGFS, -7.4 ± 1.8; TLFS, -8.7 ± 1.5; P < .0001). Multivariate analysis revealed that TLFS was the only significant factor for an improved VCSS (hazard ratio, 0.63; 95% confidence interval, 0.32-0.96; P < .0001). The need for additional second-stage sclerotherapy was significantly avoided in the TLFS group (n = 10; 10%) compared with the UGFS group (n = 51; 54%; P < .0001). CONCLUSIONS: TLFS combined with EVLA is a safe and feasible procedure that improves the VCSS and reduces the need for additional second-stage interventions compared with UGFS combined with EVLA.
引用
- Watanabe S, Okamura A, Iwamoto M, et al. A randomized controlled trial to evaluate the safety and efficacy of transluminal injection of foam sclerotherapy compared with ultrasound-guided foam sclerotherapy during endovenous catheter ablation in patients with varicose veins. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34252576. doi:10.1016/j.jvsv.2021.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。